← Eichor
Condition: Chidamide Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Chidamide

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05931263Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radio
Phase 1 · 1 location(s) · West China Hospital · NCT07545967Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05566054Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular H
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05572983SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06122389CR-CHOP+X in Previously Untreated DEL
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06701357Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Ne
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06532552Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Pr
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05958719Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07397832Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05768503VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06220162An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal A
EARLY_Phase 1 · 1 location(s) · Second Affiliated Hospital of Soochow University · NCT07598578CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Phase 2 · 1 location(s) · First Affiliated Hospital of Ningbo University · NCT06764017Linperlisib Combined With Chidamide in Patients With PTCL
Phase 1/Phase 2 · 6 location(s) · Yanyan Liu · NCT06421948Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transpla
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06393361Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT07514936Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07074457Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07058103Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Phase 2 · 5 location(s) · Shanghai Jiao Tong University School of Medicine · NCT05881265Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Phase 2 · 1 location(s) · Shanxi Province Cancer Hospital · NCT06637007Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2 · 13 location(s) · Guangdong Provincial People's Hospital · NCT06451861Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07093710Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcin
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07570849Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06891157A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide i
Phase 2 · 1 location(s) · The First Hospital of Jilin University · NCT06979908Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07159620Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Phase 2 · 1 location(s) · Ou Bai, MD/PHD · NCT07493148Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Phase 1/Phase 2 · 1 location(s) · Sichuan University · NCT05682755
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.